Le Lézard
Classified in: Health
Subjects: PDT, FDA

Hematogenix Launches FDA Approved Companion Diagnostic Immuno-oncology Test for Triple-Negative Breast Cancer

TINLEY PARK, Ill., March 12, 2019 /PRNewswire/ -- Hematogenix®- a global leader in the field of integrated pathology services for drug development and immuno-oncology testing, today announced the launch of the companion diagnostic test for the drug TECENTRIQ®. On March 8, 2019, the U.S. Food and Drug Administration (FDA) approved the immunotherapy TECENTRIQ in combination with Abraxane as frontline therapy for PD-L1-positive, unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). TECENTRIQ is the first immunotherapy approved to treat breast cancer.

Hematogenix is a global biotechnology company providing answers for tomorrow's medicine.

The companion diagnostic test that was approved by the FDA for selecting TNBC patients for TECENTRIQ is the VENTANA PD-L1 (SP142) assay.  Hematogenix has extensive experience in performing PD-L1 testing for both the diagnostic and clinical trial markets. As a global leader in immuno-oncology testing, Hematogenix has validated all commercially available, and FDA approved PD-L1 assays, since early 2016.

"We have consistently provided broad commercial access to high-quality PD-L1 testing. It is our continued mission to help our physicians identify the most appropriate treatment options for their patients," said Hytham Al-Masri, M.D., CEO and Founder of Hematogenix. "This new advance in immunotherapy for patients with metastatic triple-negative breast cancer brings additional options for patients fighting this aggressive disease. I am proud of my team's involvement in the continuous research in this ground-breaking area of cancer."

The VENTANA PD-L1 (SP142) assay is an immunohistochemical assessment of the programmed death-ligand 1 (PD-L1) protein in tumor cells and tumor-infiltrating immune cells in formalin-fixed, paraffin-embedded (FFPE) tumor tissue.

About Hematogenix
Hematogenix is a global biotechnology company providing reference laboratory services. Their team of board-certified clinical, anatomic and research pathologists works in conjunction with top scientists from around the world to provide quality testing, consultation, and guidance for all aspects of the company's pharma and diagnostic services. Hematogenix offers an array of biomarker development and testing services which navigate the complexities of human subject clinical trials. The company's clinical laboratories are CAP, and CLIA certified, GCP-compliant and serve both the pharmaceutical industry as a specialized clinical research organization and the oncology industry as a clinical and anatomical testing provider. Learn more about Hematogenix's comprehensive biomarker development and testing services at www.hematogenix.com.

HEMATOGENIX® is a registered trademark of Hematogenix Laboratory Services, LLC.
TECENTRIQ® is a registered trademark of Genentech, Inc.

Media Contact
Kathryn E. Evans

SOURCE Hematogenix

These press releases may also interest you

17 jan 2020
Loden Vision Centers, a leading comprehensive ophthalmology company with 5 locations across the greater Nashville and surrounding areas, today announced the appointment of the senior executive, Matthew Pierre, to serve as its Chief Executive Officer....

17 jan 2020
The New Year is traditionally a time for resolutions.  Celebrity lifestyle expert Valerie Greenberg has tips for creating a "new you" for the new year. POPULAR RESOLUTION Have a fitness plan that is easy. One solution is in-home fitness...

17 jan 2020
Alan Alda, the Emmy Award-winning actor, director and writer who has become a leading advocate for effective science communication, has partnered with the renowned scientific institute Scripps Research to bring immersive communication training to...

17 jan 2020
The global PD-1 and PD-L1 inhibitors market is poised to grow by USD 21.2 billion during 2019-2023, progressing at a CAGR of over 19% during the forecast period. Request Free Sample Pages Read the 118-page research report with TOC on "PD-1 and...

17 jan 2020
Therapy and Beyond, a leading provider of autism treatment for individuals, will expand its applied behavior analysis and autism therapy programs to a new location in Sugar Land, TX. About Applied Behavior Analysis Applied Behavior Analysis (ABA...

17 jan 2020
Summary Product: PMS-Nystatin Oral Suspension 100,000 units/mL (DIN 00792667), Lot 681044, Expires 30-11-2021. Issue: Product may contain clumps or jelly-like material, which may lead to choking. Newborns, infants and people with difficulty...

News published on 12 march 2019 at 15:59 and distributed by: